R. Wessalowski et al., TOTAL-BODY HYPERTHERMIA IN COMBINATION WITH ETOPOSIDE AND MELPHALAN IN A CHILD WITH ACUTE MYELOMONOCYTIC LEUKEMIA, Medical and pediatric oncology, 22(1), 1994, pp. 61-65
In vitro and clinical studies have shown antineoplastic effects of hyp
erthermia alone and in combination with other treatment modalities. Sy
nergistic cytotoxic effects of chemotherapy and hyperthermia have been
demonstrated on leukemic cell clones in vitro. It seems that hyperthe
rmia is effective in overcoming chemotherapy resistance. Several group
s treated solid tumors by using total body hyperthermia (TBHT). Howeve
r, only a few studies have been reported investigating the clinical ef
fects of TBHT in myeloproliferative disorders. We report the case of a
7-year-old boy with myelomonocytic leukemia treated with TBHT (2 hour
s, 42-degrees-C) combined with etoposide (600 mg/m2), melphalan (30 mg
/m) and hyperglycemia (200-300 mg/dl). Within 24 hours after TBHT, the
leukemic cells decreased after TBHT from 53,000/mul to zero. Skin leu
kemic infiltrates, resistant to conventional treatment, also responded
well. Although our patient relapsed 34 days after TBHT, these results
indicate that TBHT in combination with cytotoxic treatment may be a u
seful treatment modality in refractory leukemia. (C) 1994 Wiley-Liss,
Inc.